Bisphosphonate-associated atypical sub-trochanteric femur fractures: Paired bone biopsy quantitative histomorphometry before and after teriparatide administration

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 5, 2015, Pages 477-482

  Miller, Paul D ^a   McCarthy, Edward F ^b  

^a University of Colorado Health Sciences Center   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atypical femur fractures; Atypical sub trochanteric femur fractures; Bisphosphonate associated femur fractures; Bone histomorphometry in bisphosphonate femur fractures; Teriparatide in bisphosphonate femur fractures

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIFEDIOL; CREATININE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; TETRACYCLINE; TRANSCRIPTION FACTOR PAX5; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; ATYPICAL FEMUR SUBTROCHANTERIC FRACTURE; ATYPICAL SUBTROCHANTERIC FEMUR FRACTURE; BONE BIOPSY; BONE MARROW BIOPSY; BONE MASS; BONE MINERALIZATION; BONE REMODELING; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FEMUR SUBTROCHANTERIC FRACTURE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; ILIAC CREST; INTRAMEDULLARY NAIL; LONG TERM CARE; MORPHOMETRICS; OSSIFICATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STRESS FRACTURE; TREATMENT DURATION; VERY ELDERLY; BONE DENSITY; CHEMICALLY INDUCED; DRUG EFFECTS; FEMUR FRACTURE; MIDDLE AGED; OSTEOPOROSIS; PATHOLOGY;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMORAL FRACTURES; HUMANS; MIDDLE AGED; OSTEOPOROSIS; TERIPARATIDE;

EID: 84926292759     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.09.005     Document Type: Article

References (47)

1. Abrahamsen B., Eiken P., Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095-1102.
2. Giusti A., Hamdy N.A., Dekkers O.M., Ramautar S.R., Dijkstra S., Papapoulos S.E. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011, 48:966-971.
3. Rizzoli R., Akesson K., Bouxsein M., Kanis J.A., Napoli N., Papapoulos S., et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011, 22:373-390.
4. Schilcher J., Michaelsson K., Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011, 364:1728-1737.
5. Gedmintas L., Solomon D.H., Kim S.C. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013, 28:1729-1737.
6. Meier R.P.H., Perneger T.V., Stern R., Rizzoli R., Peter R.E. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012, 172:930-936.
7. Feldstein A.C., Black D., Perrin N., Rosales A.G., Friess D., Boadman D., et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012, 27:977-986.
8. Ng A.C., Drake T., Clarke B.L., Sems S.A., Achenach S.J., Atkinson E.J., et al. Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984-2007. Osteoporos Int 2012, 23:1721-1726.
9. Hedlund R., Lindgren U. Epidemiology of diaphyseal femoral fracture. Acta Orthop Scand 1966, 57:423-427.
10. Arenson T.J., Melton L.J., Lewallen D.G., O'Fallon W.M. Epidemiology of diaphyseal and distal femoral fractures in Rochester, Minnesota, 1965-1984. Clin Orthop Relat Res 1988, 234:188-194.
11. Nieves J.W., Bilezikian J.P., Lane J.M., Einhorn T.A., Wang Y., Steibuch M., et al. Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2010, 21:399-408.
12. Whitaker M., Guo J., Kehoe T., Benson G. Bisphosphosphonates for osteoporosis-where do we go from here?. N Engl J Med 2012, 366:2048-2051.
13. Shane E., Burr D., Ebeling P.R., Abrahamason B., Adler R., Brown T.D., et al. Atypical subtrochanteric and diaphyseal femora fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010, 25:2267-2294.
14. Shane E., Burr D., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014, 29:1-23.
15. McClung M., San Martin J., Miller P.D., Civetelli R., Bandeeira F., Omizo M., et al. Teriparatide and alendronate increase bone mass by opposite effects on bone remodeling. Arch Intern Med 2005, 165:1762-1768.
16. Dobnig H., Stephan J.J., Burr D.B., Li J., Michalska D., Spios A., et al. Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate. J Bone Miner Res 2009, 24:1998-2006.
17. Parfitt A.M., Drezner M.C., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 1987, 2:595-610.
18. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., et al. Standarized nomenclature, symbols and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2013, 28:2-17.
19. Ott S.M. What is the optimal duration of bisphosphonate therapy?. Cleve Clin J Med 2010, 78:619-630.
20. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997, 15:100. 1475-80.
21. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:3219-3228.
22. Diab DL, Watts NB, Miller PD. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R, Feldman D, Dempster D, Lucket M, Cauley J, editors. Osteoporosis. 4th ed. Waltham, MA; 2013. p. 1859-72.
23. Black D.M., Schwartz A.V., Ensrud K.E., Cauley J.A., Levis S., Quandt S.A., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. J Am Med Assoc 2006, 296:2927-2938.
24. Black D.M., Reid I.R., Boonen S., Bucci-Rechtweg C., Cauley J.A., Cosman F., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012, 27:243-254.
25. Boonen S., Ferrari S., Miller P.D., Eriksen E.F., Sambrook P.N., Compston J., et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res 2012, 27:963-974.
26. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011, 22(12):2951-2961.
27. van der Meulen M.C., Boskey A.L. Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality. Arthritis Res Ther 2012, 14:220.
28. Sutton R.A., Mumm S., Coburn S.P., Ericson K.L., Whyte M.P. "Atypical femoral fractures" during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res 2012, 27:987-994.
29. Whyte M.P. Atypical femoral fractures, bisphosphonates, and adult hypophosphatasia. J Bone Miner Res 2009, 24:1132-1134.
30. Khosla S., Bilezikian J.P., Dempster D.W., Lewiecki E.M., Miller P.D., Neer R.M., et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012, 97:2272-2282.
31. McClung M., Harris S.T., Miller P.D., Bauer D.C., Davison K.S., Dian L., et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013, 126:13-20.
32. Adams A.L., Xue F., Wang J.Q., Dell R.M., Ott S.M., Critchlow C. Atypical femoral fracture risk factors: a population-based case-controlled study (abstract) 2014, World Congress of Osteoporosis, Selville, Spain.
33. Malluche H.H., Meyer W., Sherman D., Massry S.G. Quantitative bone histology in 84 normal American subjects. Calcif Tissue Int 1982, 34:449-455.
34. Kimmel D.B., Recker R.R., Gallagher J.C., Vaswani A.S., Aloia J.F. A comparison of iliac bone histomorphometric data in post-menopausal osteoporotic and normal subjects. Bone Miner 1990, 11:217-235.
35. Chiang C.Y., Zebaze R.M., Ghasem-Zadeh A., Iuliano-Burns S., Hardidge A., Seeman E. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonates. Bone 2013, 52:360-365.
36. Gomberg S.J., Wustrack R.L., Napoli N., Arnaud C.D., Black D.M. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011, 96:1627.
37. Carvalho N.N., Voss L.A., Almeida M.O., Salgado C.L., Bandeira F. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 2011, 96:2675-2680.
38. Vasikaran S., Eastell R., Bruyère O., Foldes A.J., Garnero P., Griesmacher A., et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011, 22:391-420.
39. Bauer D., Krege J., Lane N., Leary E., Libanati C., Miller P.D., et al. National Bone Health Alliance Bone Marker Turnover Project: current practices and the need for U.S. harmonization, standardization and common reference ranges. Osteoporos Int 2012, 23(10):2425-2433.
40. Krege J.H., Lane N.E., Harris J.M., Miller P.D. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int 2014, 25(9):2159-2171.
41. Somford M.P., Draijer F.W., Thomassen B.J., Chavassieux P.M., Boivin G., Papapoulos S.E. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24:1736-1740.
42. Dell R.M., Adams A.L., Greene D.F., Funshashi T.T., Silverman S.L., Eisemon E.O., et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012, 27:2544-2550.
43. Marcus R. Present at the beginning: a brief history of teriparatide. Osteoporos Int 2011, 22(8):2241-2248.
44. Rubery P.T., Bukata S.V. Terparatide may accelerate healing in delayed-unions in type III odontoid fractures. J Spinal Disord Tech 2010, 23:151-155.
45. Inoue G.1, Ueno M., Nakazawa T., Imura T., Saito W., Uchida K., et al. Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine 2014, 6:1-7. [Epub ahead of print].
46. Ohtori S., Inoue G., Orita S., Yamauchi K., Eguchi Y., Ochiai N., et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spine fusion in postmenopausal women with osteoporosis from a bone quality perspective. Spine 2014, 2-14. [Epub ahead of publication]. 10.1097/BRS.0b013e31828826dd.
47. Inoue G., Ueno M., Nakazawa T., Imura T., Saito W., Uchida K., et al. Teriparatide increases the insertional torque of pedicle screws during fusion surgery in patients with postmenopausal osteoporosis. J Neurosurg Spine 2014, 6:1-7. [Epub ahead of print].